- Home
- UTMD vs TLSA Comparison
UTMD vs TLSA Comparison
Compare UTMD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UTMD | TLSA |
|---|---|---|
| Founded | 1978 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.4M | 166.7M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | UTMD | TLSA |
|---|---|---|
| Price | $62.64 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.0K | ★ 93.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $40,903,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.27 | $0.73 |
| 52 Week High | $68.71 | $2.60 |
Technical Indicators
Market Signals| Indicator | UTMD | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 35.66 |
| Support Level | $60.00 | N/A |
| Resistance Level | $64.21 | $1.56 |
| Average True Range (ATR) | 1.69 | 0.10 |
| MACD | -0.65 | -0.01 |
| Stochastic Oscillator | 9.43 | 9.46 |
Price Performance
Historical ComparisonAbout UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.